TY - JOUR
T1 - Eosinophil and mast cell Siglecs
T2 - From biology to drug target
AU - O'Sullivan, Jeremy A.
AU - Chang, Alan T.
AU - Youngblood, Bradford A.
AU - Bochner, Bruce S.
N1 - Funding Information:
This work was supported in part by grants from National Institute of Allergy and Infectious Diseases (U19AI136443 to B.S.B. and U19AI070535 subaward 107905120 to J.A.O.). We also thank Jacqueline Schaffer for generating artwork used in this review.
Publisher Copyright:
© 2020 Society for Leukocyte Biology
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.
AB - Mast cells and eosinophils are innate immune cells involved in both acute and chronic inflammatory responses. Siglecs are a family of cell surface receptors that share sialic acid binding activity. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Because of this, Siglecs have garnered interest as potential drug targets using strategies ranging from biologics to ligand-directed nanoparticles. This mini-review will highlight the state of our knowledge regarding human eosinophil and mast cell Siglecs, their biology, what they recognize, tools developed for in vitro and preclinical experimentation, and the status of ongoing efforts to develop drugs that engage eosinophil and mast cell Siglecs for potential therapeutic benefit.
KW - AK002
KW - Siglec
KW - antolimab
KW - eosinophils
KW - ligands
KW - mast cells
KW - signaling
UR - http://www.scopus.com/inward/record.url?scp=85078675730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078675730&partnerID=8YFLogxK
U2 - 10.1002/JLB.2MR0120-352RR
DO - 10.1002/JLB.2MR0120-352RR
M3 - Review article
C2 - 31965606
AN - SCOPUS:85078675730
VL - 108
SP - 73
EP - 81
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
SN - 0741-5400
IS - 1
ER -
